PATIENT NOTIFICATION SYSTEM
Confidential notification within 24 hours of therapy withdrawals & recalls
 
Welcome to PPTA

The Plasma Protein Therapeutics Association (PPTA) is the primary advocate for the world’s leading source plasma collectors and producers of plasma-based and recombinant biological therapeutics.

The medicines produced by PPTA members are used in treating life-threatening diseases and serious medical conditions including bleeding disorders, immune system deficiencies, alpha-1 antitrypsin deficiency, burns and shock.

As the global representative for the plasma collection and therapeutics industry, PPTA works cooperatively with patient groups, policymakers, regulatory agencies and other stakeholders to address critical issues.

Watch Video:
Learn About Plasma Protein Therapies

Learn About Plasma Protein Therapies
Watch video.

Kedrion Earns International Quality Certification For Manufacturing Lifesaving Plasma-Derived Therapies
ANNAPOLIS, MD (February 5, 2010) - The Plasma Protein Therapeutics Association (PPTA) announced today that Kedrion is the sixth company to be certified through its international Quality Standards of Excellence, Assurance, and Leadership (QSEAL) Program, which evaluates manufacturers of plasma protein therapies.  Read More
PPTA Launches New Website Tool
ANNAPOLIS, MD (September 23, 2009) – Visitors to DonatingPlasma.org can more easily find their local plasma donation center now with an improved search feature. The Plasma Protein Therapeutics Association (PPTA), which developed the website to raise awareness of plasma donation, unveils the tool today, seeking to build on the importance of providing up-to-date information to donors who provide plasma needed to manufacture life-saving therapies.   Read More
Plasma Protein Therapeutics Association Urges CMS for Appropriate Hospital Outpatient Reimbursement
ANNAPOLIS, MD—Aug. 11, 2009—The Plasma Protein Therapeutics Association (PPTA) supports the favorable recommendation of average sales price (ASP) + 6 percent for reimbursement of separately paid drugs and biologics in the hospital outpatient setting made by the Centers for Medicare and Medicaid Services’ (CMS) Advisory Panel on Ambulatory Payment Classification (APC) at its August 5-7 meeting, although third party data maintains that ASP +12 percent is the appropriate reimbursement level.   Read More

IPPC 2010 - 3/16/2010
PPTA 2010 International Plasma Protein Congress
Read More

View Calendar of Events
 
HOMECONTACTNEWSROOMSITE MAPTERMS OF USEPRIVACY POLICY